437 related articles for article (PubMed ID: 19634158)
1. Diffuse large B-cell lymphoma: clinical characterization and prognosis of Waldeyer ring versus lymph node presentation.
Qi SN; Li YX; Wang H; Wang WH; Jin J; Song YW; Wang SL; Liu YP; Zhou LQ; Yu ZH
Cancer; 2009 Nov; 115(21):4980-9. PubMed ID: 19634158
[TBL] [Abstract][Full Text] [Related]
2. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin.
López-Guillermo A; Colomo L; Jiménez M; Bosch F; Villamor N; Arenillas L; Muntañola A; Montoto S; Giné E; Colomer D; Beà S; Campo E; Montserrat E
J Clin Oncol; 2005 Apr; 23(12):2797-804. PubMed ID: 15728226
[TBL] [Abstract][Full Text] [Related]
3. Clinical disparity and favorable prognoses for patients with Waldeyer ring extranodal nasal-type NK/T-cell lymphoma and diffuse large B-cell lymphoma.
Wu RY; Li YX; Wang WH; Jin J; Wang SL; Liu YP; Song YW; Fang H; Ren H; Liu QF; Wang ZY; Qi SN; Lu NN; Chen B; Zhang XM; Zhou LQ; Liu XF; Yu ZH
Am J Clin Oncol; 2014 Feb; 37(1):41-6. PubMed ID: 22992625
[TBL] [Abstract][Full Text] [Related]
4. [Clinical characteristics and prognosis of diffuse large B-cell lymphoma].
Yang BY; Yong WB; Zhu J; Zheng W; Zhang YT; Wang XP; Meng SN
Zhonghua Zhong Liu Za Zhi; 2005 Mar; 27(3):174-6. PubMed ID: 15946571
[TBL] [Abstract][Full Text] [Related]
5. Primary testicular diffuse large B-cell lymphoma: a population-based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of rituximab.
Gundrum JD; Mathiason MA; Moore DB; Go RS
J Clin Oncol; 2009 Nov; 27(31):5227-32. PubMed ID: 19770371
[TBL] [Abstract][Full Text] [Related]
6. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
[TBL] [Abstract][Full Text] [Related]
7. Comparison of peripheral T-cell lymphomas and diffuse large B-cell lymphoma.
Tomita N; Motomura S; Hyo R; Takasaki H; Takemura S; Taguchi J; Fujisawa S; Ogawa K; Ishigatsubo Y; Takeuchi K
Cancer; 2007 Mar; 109(6):1146-51. PubMed ID: 17311304
[TBL] [Abstract][Full Text] [Related]
8. Prognosis of localized diffuse large B-cell lymphoma in younger patients.
Møller MB; Christensen BE; Pedersen NT
Cancer; 2003 Aug; 98(3):516-21. PubMed ID: 12879468
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics and prognosis of primary Waldeyer's ring and lymph node diffuse large B-cell lymphoma in the rituximab era.
Jing XM; Yu JR; Luo YK; Zhang SC; Liu JF; Li L; Wu P; Zhang ZH
Leuk Res; 2017 Sep; 60():89-93. PubMed ID: 28772206
[TBL] [Abstract][Full Text] [Related]
10. Reassessment of the prognostic factors of international prognostic index (IPI) in the patients with diffuse large B-cell lymphoma in an era of R-CHOP in Chinese population.
Yang S; Yu Y; Jun-Min L; Jian-Qing M; Qiu-Sheng C; Yu C; Wei-Li Z; Jian-Hua Y; Hui-Jin Z; Yan W; Li W; Shu C; Zhi-Xiang S
Ann Hematol; 2009 Sep; 88(9):863-9. PubMed ID: 19205655
[TBL] [Abstract][Full Text] [Related]
11. [Clinical characteristics, cell origin and prognosis of primary gastrointestinal diffuse large B-cell lymphoma: a report of 40 cases].
Yang YL; Wang J; Zhao LZ; Gao ZF; Jing HM; Ke XY
Ai Zheng; 2008 Jun; 27(6):636-41. PubMed ID: 18570740
[TBL] [Abstract][Full Text] [Related]
12. Clinical behavior and treatment outcome of primary nasal diffuse large B-cell lymphoma.
Lu NN; Li YX; Wang WH; Jin J; Song YW; Zhou LQ; Wang SL; Liu YP; Liu XF; Yu ZH
Cancer; 2012 Mar; 118(6):1593-8. PubMed ID: 21837667
[TBL] [Abstract][Full Text] [Related]
13. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.
Oki Y; Yamamoto K; Kato H; Kuwatsuka Y; Taji H; Kagami Y; Morishima Y
Eur J Haematol; 2008 Dec; 81(6):448-53. PubMed ID: 18691256
[TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linformi.
Morabito F; Gallamini A; Stelitano C; Callea V; Guglielmi C; Neri S; Lazzaro A; Orsucci L; Ilariucci F; Sacchi S; Vitolo U; Federico M
Cancer; 2004 Oct; 101(7):1601-8. PubMed ID: 15378507
[TBL] [Abstract][Full Text] [Related]
15. Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays.
Zinzani PL; Dirnhofer S; Sabattini E; Alinari L; Piccaluga PP; Stefoni V; Tani M; Musuraca G; Marchi E; Falini B; Baccarani M; Pileri SA
Haematologica; 2005 Mar; 90(3):341-7. PubMed ID: 15749666
[TBL] [Abstract][Full Text] [Related]
16. Primary diffuse large B-cell lymphoma of the tonsil: is a higher radiotherapy dose required?
Laskar S; Bahl G; Muckaden MA; Nair R; Gupta S; Bakshi A; Gujral S; Shet T; Shrivastava SK; Dinshaw KA
Cancer; 2007 Aug; 110(4):816-23. PubMed ID: 17582622
[TBL] [Abstract][Full Text] [Related]
17. Variable clinical presentations of nasal and Waldeyer ring natural killer/T-cell lymphoma.
Li YX; Liu QF; Fang H; Qi SN; Wang H; Wang WH; Song YW; Lu J; Jin J; Wang SL; Liu YP; Lu N; Liu XF; Yu ZH
Clin Cancer Res; 2009 Apr; 15(8):2905-12. PubMed ID: 19318493
[TBL] [Abstract][Full Text] [Related]
18. Analysis of clinical and immunophenotypic features along with treatment outcomes of diffuse large B cell lymphoma patients, based on the involvement of nodal or extranodal primary sites.
Wang C; Li W; Liu C; He H; Bai O
Blood Cells Mol Dis; 2016 Mar; 57():42-9. PubMed ID: 26852654
[TBL] [Abstract][Full Text] [Related]
19. Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma.
Lech-Maranda E; Bienvenu J; Michallet AS; Houot R; Robak T; Coiffier B; Salles G
Eur Cytokine Netw; 2006 Mar; 17(1):60-6. PubMed ID: 16613764
[TBL] [Abstract][Full Text] [Related]
20. High Ki67 index and bulky disease remain significant adverse prognostic factors in patients with diffuse large B cell lymphoma before and after the introduction of rituximab.
Gaudio F; Giordano A; Perrone T; Pastore D; Curci P; Delia M; Napoli A; de' Risi C; Spina A; Ricco R; Liso V; Specchia G
Acta Haematol; 2011; 126(1):44-51. PubMed ID: 21430371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]